Matthew P. Kosloski

Jul 30, 2024 | ascpt.onlinelibrary.wiley.com | Emma Guttman-Yassky |Michael J. Cork |Margitta Worm |Matthew P. Kosloski

WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? Interleukin-33 (IL-33), a proinflammatory alarmin cytokine released by damaged epithelial tissue cells, initiates and amplifies both type 1 and type 2 inflammatory cascades. IL-33 has been suggested as having a role in atopic dermatitis (AD), a chronic, relapsing type 2 inflammatory disease of the skin. Itepekimab is a novel human IgG4P monoclonal antibody against IL-33, currently in development for chronic obstructive pulmonary disease (COPD).